Trace Biosciences, a clinical-stage biotechnology firm, has announced a significant strategic investment from Axogen, Inc., a global leader in peripheral nerve repair. This investment is part of Trace's Series A financing round and is set to accelerate the clinical development of its pioneering nerve-imaging technology. The collaboration aims to enhance surgical precision by providing surgeons with unprecedented real-time visualization of nerve tissues, potentially transforming patient outcomes in a wide array of procedures.
A Strategic Alliance to Advance Nerve Care
The investment from Axogen marks a pivotal moment for Trace Biosciences as it continues to advance its technology through rigorous clinical evaluation. Axogen, known for its comprehensive portfolio of nerve repair solutions, views this partnership as a direct alignment with its core mission to improve the standard of care for nerve injuries. While Axogen is a key strategic partner in the Series A round, Trace Biosciences anticipates that additional investors will join the financing effort.
Leadership from both companies highlighted the synergy of the partnership. Connor Barth, CEO of Trace Biosciences, welcomed Axogen's support, noting it strengthens their ability to bring enhanced nerve visibility to surgeons. Echoing this sentiment, Axogen CEO Michael Dale emphasized that the ability to see a nerve is fundamental to its protection and repair, stating that this technology is foundational to improving patient care and making nerve function restoration a standard expectation.
Revolutionizing Surgical Visibility with Nerve Trace
At the heart of this collaboration is Nerve Trace, a novel near-infrared fluorescence imaging agent developed by Trace Biosciences. This technology is engineered to provide surgeons with a direct, real-time view of nerves during surgical procedures. Its unique capability allows it to illuminate nerve structures that would otherwise be completely obscured by surrounding tissues, offering a new level of clarity in the operating room.
The clinical applications for Nerve Trace are twofold and address critical surgical challenges. Firstly, the technology serves a protective function, enabling surgeons to clearly identify and avoid critical nerves during a broad range of operations, thereby preventing unintentional damage. Secondly, for cases involving existing nerve injuries, it allows for more precise localization and assessment of the damaged nerve, which is crucial for facilitating a more effective surgical repair.
Navigating the Path to Regulatory Approval
Trace Biosciences has already achieved a significant regulatory milestone with its lead candidate, Nerve Trace Dx. The company received clearance for its Investigational New Drug (IND) application from the FDA in December 2025, a key step in the clinical development pathway. Following this clearance, a Phase I clinical trial was initiated to formally evaluate the imaging agent's safety and feasibility in surgical patients.
The capital raised through the Series A financing round will be instrumental in propelling Nerve Trace Dx into its next stages of development. These funds are specifically earmarked to support the execution of larger Phase II and III clinical trials, which are required to gather further data on efficacy and safety. The successful completion of these advanced trials is a prerequisite for submitting a New Drug Application (NDA) to the FDA for market approval.
This strategic investment by Axogen in Trace Biosciences represents a powerful endorsement of a technology poised to redefine surgical standards for nerve protection and repair. By combining Axogen's market leadership in nerve solutions with Trace's innovative imaging platform, the collaboration is set to accelerate the journey of Nerve Trace from the laboratory to the operating room. Ultimately, this partnership promises to enhance surgical safety, improve the efficacy of nerve repair, and deliver better outcomes for patients worldwide.